A study published in JACC: Advances demonstrated that a risk prediction algorithm incorporating HeartBeam's portable ECG device can accurately identify heart attack risk in patients presenting with chest pain, according to HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care.
The proof-of-concept study evaluated 184 patients and found that the algorithm achieved an “area under the curve” (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms. The AUC rose to 92.9% when a personal, symptom-free baseline ECG was available for comparison. The company stated that these results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program.
The HeartBeam device is a credit card-sized, cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable use, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025.
This study's findings could have significant implications for the early detection of heart attacks, potentially reducing time to treatment and improving patient outcomes. By enabling accurate risk assessment in a portable format, the technology may help triage patients more effectively, especially in settings where immediate access to a full 12-lead ECG is not available. The ability to compare readings with a personal baseline further enhances diagnostic accuracy, suggesting that routine baseline ECGs could become a valuable preventive tool.
The company holds over 20 issued patents related to its technology enablement. For more information about the HeartBeam System and its cleared indications for use, refer to the company's website at https://www.heartbeam.com/indications. The full press release is available at https://ibn.fm/ainxV.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's SEC filings. No undue reliance should be placed on such statements.
